RADEK SKODA to Disease Models, Animal
This is a "connection" page, showing publications RADEK SKODA has written about Disease Models, Animal.
Connection Strength
0.693
-
Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021 Mar; 165(1):26-33.
Score: 0.340
-
Loss of Socs2 improves molecular responses to IFNa in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F. Leukemia. 2025 Apr; 39(4):876-887.
Score: 0.113
-
Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN. Blood. 2015 Mar 26; 125(13):2131-40.
Score: 0.056
-
Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs. Blood. 2014 Jun 19; 123(25):3943-50.
Score: 0.053
-
Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. Blood. 2013 Feb 14; 121(7):1188-99.
Score: 0.048
-
Thrombocytosis. Hematology Am Soc Hematol Educ Program. 2009; 159-67.
Score: 0.037
-
HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis. Nat Commun. 2018 04 12; 9(1):1431.
Score: 0.018
-
Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging. J Thromb Haemost. 2014 Dec; 12(12):2120-30.
Score: 0.014
-
Haemorrhagic and thrombotic diatheses in mouse models with thrombocytosis. Thromb Haemost. 2015 Feb; 113(2):414-25.
Score: 0.014